Latest H5N1 clinical trials Stories
Using live but weakened malaria parasites as the basis of a vaccine represents a potentially encouraging anti-malaria strategy.
New research from the Trudeau Institute may help to explain why live attenuated influenza vaccine (LAIV), commonly known as FluMist, elicits protection.
ATLANTA, Aug. 16, 2011 /PRNewswire/ -- GeoVax Labs, Inc.
SAN DIEGO, Aug.
QUEBEC CITY, QC, Aug. 12, 2011 /PRNewswire/ - Medicago Inc.
BEIJING, June 28, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today the commencement of the Phase II clinical trial for its proprietary inactivated EV71 vaccine against Hand, Foot and Mouth Disease (HFMD).
NESS ZIONA, Israel, June 16, 2011 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) [http://www.biondvax.com ] today announced positive results from its first Phase II clinical trial of the Multimeric-001 Universal Influenza Vaccine.
The need to create a new flu vaccine annually could be eliminated with a universal influenza vaccine that targets a protein common to all strains of influenza A.
- All tested doses were found safe and well-tolerated - - A single dose of 5 Âµg met the 3 CHMP immunogenicity criteria - QUEBEC CITY, June 8, 2011 /PRNewswire/ - Medicago Inc.
- Pertaining to the surface or end opposite to the mouth in a radiate animal.